5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $45M | -$39M | 84.6% | -59.7% | -$19M | $33M | $20M |
| 2024 | $29M | -$30M | 86.1% | -122.9% | -$41M | $22M | $9M |
| 2023 | $19M | -$59M | 85.9% | -294.3% | -$51M | $0 | $12M |
| 2022 | $12M | -$47M | 81.8% | -293.9% | -$33M | — | $9M |
| 2021 | — | $5M | — | — | — | — | $200884 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $9M | $2M | 86.2% | -94.5% | -$7M | $33M | $57M |
| Dec '25 | $13M | -$10M | 86.7% | -24.8% | -$3M | $33M | $20M |
| Sep '25 | $12M | -$11M | 83.5% | -77.9% | -$4M | $33M | $23M |
| Jun '25 | $11M | -$8M | 83.9% | -65.4% | -$7M | $32M | $26M |
| Mar '25 | $9M | -$10M | 83.7% | -79.9% | -$5M | $32M | $13M |
| Dec '24 | $8M | -$10M | 85.3% | -91.8% | -$6M | $22M | $9M |
| Sep '24 | $7M | -$2M | 86.3% | -118.9% | -$11M | $22M | $11M |
| Jun '24 | $7M | -$4M | 87.6% | -111.0% | -$13M | $21M | $16M |
| Mar '24 | $6M | -$13M | 85.0% | -180.8% | -$11M | — | $4M |
| Dec '23 | $6M | -$36M | 89.8% | -249.0% | -$10M | $0 | $12M |
| Sep '23 | $5M | -$1M | 88.7% | -358.5% | -$22M | — | $21M |
| Jun '23 | $5M | -$14M | 83.3% | -247.9% | -$9M | — | $103975 |
| Mar '23 | $3M | -$8M | 77.8% | -339.2% | -$11M | — | $136798 |
| Dec '22 | $3M | -$23M | 74.7% | -364.9% | -$9M | — | $9M |
| Sep '22 | $4M | -$8M | 82.1% | -206.8% | — | — | $207598 |
| Jun '22 | — | -$9M | — | — | — | — | $69182 |
| Mar '22 | — | $3M | — | — | — | — | $50930 |
| Dec '21 | — | $3M | — | — | — | — | $200884 |
| Sep '21 | — | $2M | — | — | — | — | $277805 |
| Jun '21 | — | $378866 | — | — | — | — | $642944 |
How the market has priced TLSI against its own fundamentals since 2023-08 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 4 years, TriSalus Life Sciences, Inc.'s revenue has grown 53.9% per year. These are computed facts, not advice.
As of FY2025, TriSalus Life Sciences, Inc. reported $33M of total debt against $20M of cash; operating income covered interest expense -4.9×.
In FY2025, gross margin was 84.6%, operating margin -59.7%, and net margin -86.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.